Article
Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review.
Pediatric nephrology (Berlin, Germany) - 1 Jun 2021
Malakasioti Georgia, Iancu Daniela, Tullus Kjell
Abstract excerpt
BACKGROUND: Calcineurin inhibitor (CNI) use in genetic steroid-resistant nephrotic syndrome (SRNS) is controversial as response rate is reported to be lower than non-genetic disease and no plausible mechanism of action is known. METHODS: We reviewed PubMed for publications on CNI use in hereditary SRNS to determine (1) CNI response rate; (2) impact of response on renal outcome; and (3) clinical and molecular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
